|
gptkbp:instanceOf
|
gptkb:chemical_compound
antineoplastic agent
anthracenedione
|
|
gptkbp:approvalYear
|
1987
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01DB07
|
|
gptkbp:brand
|
gptkb:Novantrone
|
|
gptkbp:CASNumber
|
65271-80-9
|
|
gptkbp:category
|
immunosuppressant
cytotoxic drug
|
|
gptkbp:color
|
blue
|
|
gptkbp:contraindication
|
pregnancy
severe hepatic impairment
cardiac dysfunction
|
|
gptkbp:developedBy
|
gptkb:Immunex
|
|
gptkbp:eliminationHalfLife
|
75 hours
|
|
gptkbp:excretion
|
renal
biliary
|
|
gptkbp:hasMolecularFormula
|
C22H28N4O6
|
|
gptkbp:hasSMILES
|
C1=CC(=C2C(=C1)C(=O)C3=C(C2=O)C=CC(=C3NCCNCCO)NCCNCCO)O
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
mitoxantrone
|
|
gptkbp:KEGGID
|
D00451
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
DNA intercalation
topoisomerase II inhibition
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
444.48 g/mol
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
4068
4212
CHEMBL1411
DB01204
|
|
gptkbp:riskFactor
|
gptkb:secondary_leukemia
infertility
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
hair loss
cardiotoxicity
myelosuppression
|
|
gptkbp:solubility
|
water-soluble
|
|
gptkbp:UNII
|
Q88T4F2TZ8
|
|
gptkbp:usedFor
|
gptkb:acute_myeloid_leukemia
leukemia
prostate cancer
multiple sclerosis
|
|
gptkbp:bfsParent
|
gptkb:multidrug_resistance-associated_protein_1
|
|
gptkbp:bfsLayer
|
6
|